Pharma Business - January 18, 2021
AstraZeneca’s Enhertu approved in the US
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. The approval by the Food and Drug Administration (FDA) was based on the positive results from the randomised DESTINY-Gastric01 […]
Agreement - August 11, 2020
AstraZeneca and Daiichi Sankyo enter collaboration
AstraZeneca has entered into a new global development and commercialization agreement with Daiichi Sankyo Company, for DS-1062, Daiichi Sankyo’s trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential new medicine for the treatment of multiple tumour types. DS-1062 is currently in development for the treatment of multiple tumours that commonly express the cell-surface […]
Collaboration - March 29, 2019
AstraZeneca and Daiichi Sankyo enter collaboration
The global development and commercialization collaboration agreement with Daiichi Sankyo is for trastuzumab deruxtecan (DS-8201), a antibody-drug conjugate (ADC) and potential new targeted medicine for cancer treatment. Trastuzumab deruxtecan is currently in development for the treatment of multiple HER2-expressing cancers, including breast and gastric cancer, and in patients with HER2-low expression. In 2017, trastuzumab deruxtecan was granted […]
Collaboration - March 20, 2015
AstraZeneca, Daiichi Sankyo Ink Co-Commercialization Deal
AstraZeneca Thursday signed a co-commercialization agreement with Parsippany, N.J.-based Daiichi Sankyo, Inc. worth $825 million. According to the agreement, Daiichi Sankyo will pay AstraZeneca $200 million upfront and follow-up payments up to $625 million to handle manufacturing and sales of Movantik (naloxegol), a once-daily pill for people with opioid-induced constipation (OIC). AstraZeneca will oversee manufacturing […]
Acquisition - August 6, 2013
Affibody signs deal with Daiichi Sankyo
Stockholm-based Affibody AB announces a new collaboration with Japanese Daiichi Sankyo. The license agreement regards the use of Affibody’s proprietary Albumod platform, a platform designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life. The technology will be applied on one undisclosed molecule from Tokyo-based Daiichi Sankyo’s pipeline of proprietary protein therapeutics. Affibody […]